| Issue |
SICOT-J
Volume 4, 2018
Special Issue: "Musculoskeletal tumors: Current approaches and controversies" Guest Editor: A. Kulidjian
|
|
|---|---|---|
| Article Number | 12 | |
| Number of page(s) | 8 | |
| Section | Lower Limb | |
| DOI | https://doi.org/10.1051/sicotj/2017028 | |
| Published online | 09 April 2018 | |
Review Article
Osteosarcoma: a comprehensive review
1
Department of Orthopaedic Surgery, University of California San Diego, San Diego, CA, USA
2
School of Medicine, University of Jeddah, Jeddah, Saudi Arabia
* Corresponding author: akulidjian@gmail.com
Received:
20
January
2017
Accepted:
15
April
2017
Osteosarcoma (OS) is a relatively rare tumor of bone with a worldwide incidence of 3.4 cases per million people per year. For most of the twentieth century, five-year survival rates for classic OS were very low. In the 1970s, the introduction of adjuvant chemotherapy in the treatment of OS increased survival rates dramatically. The current article reviews the various types of OS and analyzes the clinical and histological features. We also examine historical and current literature to present a succinct review of methods for diagnosis and staging, as well as treatment, and we also discuss some of the future directions of treatment.
Key words: Osteosarcoma / Review / Oncology / Sarcoma / Tumor
© The Authors, published by EDP Sciences, 2018
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.